8-K/A: Tharimmune Secures $5.35M in Registered Direct Offering

Tharimmune, Inc. announced a registered direct offering of $5.35 million in common stock and pre-funded warrants to fund working capital.

Summary

• Tharimmune, Inc. entered into a Securities Purchase Agreement for a registered direct offering to raise $5.35 million.
• The offering includes 1,188,888 shares of Common Stock (or common stock equivalents) at a price of $4.50 per share.
• Purchasers have the option to acquire Pre-Funded Warrants in lieu of shares, with a nominal exercise price of $0.001 per warrant share.
• The offering is expected to close on August 27, 2025.
• President Street Global, LLC and RF Lafferty & Co., Inc. are acting as exclusive co-placement agents, receiving a 10.0% cash fee from the aggregate gross proceeds.
• The net proceeds from the offering are designated for working capital purposes.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for working capital, which is positive for the company's operations. However, the significant dilution and high placement agent fees, along with the disclosed conflict of interest, temper the overall positive sentiment. It's a necessary step for the company but comes with notable costs and potential concerns for existing shareholders.

Positives

• Successful capital raise of $5.35 million provides necessary funding for working capital, supporting ongoing operations and strategic initiatives.
• The offering is structured to allow flexibility for purchasers with beneficial ownership limitations through the use of pre-funded warrants.
• The company has reserved a sufficient number of shares of Common Stock to cover the issuance of all securities under the offering and warrants.
• Tharimmune, Inc. is committed to maintaining its listing on the Nasdaq Stock Market LLC and ensuring the eligibility of its Common Stock for electronic transfer.

Negatives

• The issuance of new shares and warrants will result in significant dilution for existing shareholders.
• A substantial 10.0% cash fee of the aggregate gross proceeds is payable to the placement agents, reducing the net proceeds available to the company.
• A potential conflict of interest was disclosed involving Vincent LoPriore, an investment manager at Gravitas Capital LP (the largest shareholder), who is also an indirect owner of President Street Global, LLC, one of the placement agents.

Risks

• Dilution of existing shareholders' equity due to the issuance of new shares and warrants.
• Market price volatility of Common Stock, which could be negatively impacted by future open market or derivative transactions by purchasers, including short sales.
• Potential for delays in the closing of the offering if customary closing conditions are not met.
• Risks associated with the company's ability to comply with various laws and regulations, including those related to environmental protection, occupational health and safety, data privacy, and anti-corruption (FCPA, OFAC).
• Risks related to the company's internal accounting controls and disclosure procedures.
• Litigation risks, as the company is subject to various actions, suits, inquiries, and investigations.
• Dependence on the effectiveness of the registration statement for the issuance of Warrant Shares.
• Failure to maintain listing requirements on the Trading Market could negatively impact liquidity and investor confidence.

Future Outlook

The company intends to use the net proceeds from the offering for working capital purposes, supporting ongoing operations and strategic initiatives. The company also commits to maintaining its listing on the Nasdaq Stock Market LLC and ensuring the eligibility of its Common Stock for electronic transfer.

Management Comments

• Tharimmune, Inc. has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.
• Tharimmune, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sireesh Appajosyula, Chief Executive Officer.

Industry Context

This registered direct offering is a common method for publicly traded companies, particularly in the biotechnology or pharmaceutical sector (implied by 'Tharimmune'), to raise capital quickly and efficiently from institutional investors. The use of pre-funded warrants is a strategy to manage beneficial ownership limitations for large investors, which is a common consideration in such offerings. The 10% placement agent fee is within the typical range for small-cap direct offerings, reflecting the costs associated with securing capital from specialized investors.

Comparison to Industry Standards

• The 10% placement agent fee is generally considered on the higher end but not uncommon for smaller-cap companies or those in specialized sectors like biotech, where capital raises can be more challenging. For larger, more established companies, these fees are typically lower (e.g., 3-7%).
• The use of pre-funded warrants with a nominal exercise price is a standard mechanism in direct offerings to allow investors to acquire equity while staying below beneficial ownership thresholds, which is a common practice to avoid triggering certain regulatory or corporate governance provisions.
• The beneficial ownership limitation of 4.99% (or 9.99%) is a standard threshold used by investors to avoid triggering Schedule 13D filing requirements or other control-related regulations.

Corporate Governance

Related Party Transactions

• Disclosure of a potential conflict of interest: Vincent LoPriore, an investment manager at Gravitas Capital LP (the largest shareholder of the Company), is an indirect owner of the holding company of President Street Global, LLC, one of the placement agents. President Street Global is receiving a monthly retainer and a success fee, from which Mr. LoPriore may indirectly benefit.

Stakeholder Impact

• Shareholders: Significant dilution due to the issuance of new shares and warrants. Potential negative impact on share price from future trading activities by purchasers, including short sales.
• Company: Strengthened financial position with $5.35 million in capital for working capital, supporting operations and growth. Incurs substantial placement agent fees.
• Placement Agents: President Street Global, LLC and RF Lafferty & Co., Inc. receive a 10.0% cash fee, benefiting from the transaction. President Street Global also gains exclusivity for future offerings under certain conditions.
• Purchasers: Acquire shares and/or pre-funded warrants at a set price, with mechanisms to manage beneficial ownership.

Next Steps

• Closing of the offering on August 27, 2025, subject to customary conditions.
• Company to file a Current Report on Form 8-K, including the Transaction Documents as exhibits.
• Company to apply to list all newly issued shares on its Trading Market (Nasdaq).
• Company to maintain listing and eligibility for electronic transfer of Common Stock.

Key Dates

Recommendation

While the capital raise provides necessary funding for Tharimmune's working capital, the significant dilution from the offering and the high placement agent fees are notable concerns. The disclosed conflict of interest, though transparent, adds a layer of complexity. The use of proceeds for general working capital is positive for operational stability, but without specific growth initiatives or strong financial performance metrics detailed in this filing, a 'hold' recommendation is appropriate. Investors should monitor how the capital is deployed and its impact on future financial results and share price performance.

Keywords

Tharimmune, THAR, Registered Direct Offering, Common Stock, Pre-Funded Warrants, Capital Raise, SEC Filing, Form 8-K/A, Equity Offering, Working Capital, Dilution, Placement Agent, Nasdaq, Corporate Governance